DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF inhibitors, targeting both dry and wet AMD forms. Key players such as Merck, Sanofi, and Stealth BioTherapeutics are advancing late-stage trials, with some drugs nearing regulatory approval. This pipeline growth reflects rising demand for effective, durable vision-preserving treatments amid an aging population, signaling significant future market opportunities.
In 2026, international dividend ETFs like Vanguard VYMI, iShares IDV, and Schwab SCHY provide significantly higher yields than the popular U.S. dividend ETF SCHD. This yield gap stems from lower valuations and a stronger dividend payout culture in Eu...
Retirees with $500,000 to invest in dividend ETFs face a choice between Vanguard Dividend Appreciation ETF (VIG) and Schwab U.S. Dividend Equity ETF (SCHD). VIG offers lower current yield (~1.7%-1.8%) but focuses on companies with long histories of d...
Healthcare mergers and acquisitions surged to $65 billion in the first quarter of 2026, the highest since 2020, fueled by looming patent expirations on blockbuster drugs like Merck’s Keytruda. Pharma companies are acquiring innovative biotech firms t...
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
